#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	4640	16S	1529	1529	100.0	16S.l15.c30.ctg.1	2355	580.7	1	SNP	n	C1184T	0	.	.	1184	1184	C	1578	1578	C	690	C,G	565,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6900	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3967	520.6	0	.	n	.	0	T695C	SNP	695	695	T	1275	1275	C	448	C,T	364,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6900	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3967	520.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1917	1917	A	626	A	515	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6900	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3967	520.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2551	2551	C	658	C,A	551,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6900	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3967	520.6	0	.	n	.	0	C2403T	SNP	2403	2403	C	2983	2983	T	613	T,C,G	373,147,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6900	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3967	520.6	1	SNP	n	A2045G	0	.	.	2045	2045	A	2625	2625	A	656	A	562	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	6900	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3967	520.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	3177	3177	C	610	C,G	526,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	698	folP	855	855	100.0	folP.l15.c4.ctg.1	1928	108.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1287	1289	AGC	147;148;147	A;G;C	124;129;130	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1558	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3765	123.8	1	SNP	p	S91F	1	.	.	271	273	TTC	782	784	TTC	139;139;141	T;T;C	118;121;122	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1558	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3765	123.8	1	SNP	p	D95G	1	.	.	283	285	GGC	794	796	GGC	140;139;140	G;G;C	122;120;122	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	1558	gyrA	2751	2751	99.85	gyrA.l6.c17.ctg.1	3765	123.8	1	SNP	p	G95N	0	.	.	283	285	GGC	794	796	GGC	140;139;140	G;G;C	122;120;122	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	738	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1860	119.1	1	SNP	p	G45D	0	.	.	133	135	GGC	728	730	GGC	215;214;214	G;G;C	181;180;180	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	466	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1443	96.8	0	.	n	.	0	A197.	DEL	197	197	A	768	768	A	197	A	166	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1624	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3330	146.1	1	SNP	p	D86N	0	.	.	256	258	GAC	775	777	GAC	195;197;198	G;A;C	175;167;177	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1624	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3330	146.1	1	SNP	p	S87R	1	.	.	259	261	CGT	778	780	CGT	199;198;197	C,A;G;T	178,1;175;173	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1624	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3330	146.1	1	SNP	p	R87I	0	.	.	259	261	CGT	778	780	CGT	199;198;197	C,A;G;T	178,1;175;173	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1624	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3330	146.1	1	SNP	p	R87W	0	.	.	259	261	CGT	778	780	CGT	199;198;197	C,A;G;T	178,1;175;173	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1624	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3330	146.1	1	SNP	p	S88P	0	.	.	262	264	TCC	781	783	TCC	199;201;202	T;C;C	173;178;180	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	1362	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2968	137.2	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1718	1720	GGC	185;184;184	G;G,A;C	160;154,1;157	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.5.002	penA.5.002	1	1	27	1226	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2953	124.4	1	SNP	p	A311V	0	.	.	931	933	GCA	1499	1501	GCA	212;210;211	G,T;C,T;A,C	176,1;174,1;174,1	penA.5.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1226	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2953	124.4	1	SNP	p	I312M	0	.	.	934	936	ATC	1502	1504	ATC	211;211;214	A;T;C,G	176;171;182,1	penA.5.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1226	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2953	124.4	1	SNP	p	V316T	0	.	.	946	948	GTG	1514	1516	GTG	206;206;205	G;T,C,G;G,C	170;169,1,1;166,1	penA.5.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1226	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2953	124.4	1	SNP	p	V316P	0	.	.	946	948	GTG	1514	1516	GTG	206;206;205	G;T,C,G;G,C	170;169,1,1;166,1	penA.5.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1226	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2953	124.4	1	SNP	p	T484S	0	.	.	1450	1452	ACC	2018	2020	ACC	142;143;145	A;C;C,T	119;117;116,1	penA.5.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1226	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2953	124.4	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2072	2074	GCG	138;137;138	G;C,A;G	114;103,1;109	penA.5.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1226	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2953	124.4	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2072	2074	GCG	138;137;138	G;C,A;G	114;103,1;109	penA.5.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1226	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2953	124.4	1	SNP	p	G543S	1	.	.	1627	1629	AGC	2195	2197	AGC	135;135;135	A,C;G;C	109,1;108;112	penA.5.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1226	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2953	124.4	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2204	2206	GGC	138;136;138	G;G;C	112;114;114	penA.5.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.5.002	penA.5.002	1	1	27	1226	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2953	124.4	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2222	2224	CCG	138;137;137	C,G;C;G	109,1;114;110	penA.5.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1568	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3289	142.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1717	1719	CCG	146;146;145	C;C;G	116;119;113	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	816	porA	1146	1146	99.91	porA.l15.c4.ctg.1	2208	110.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	813	813	C	124	C	110	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	V75I	NONSYN	223	225	GTT	859	861	ATT	176;177;178	A;T,G;T,G	151;153,1;153,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	T89S	NONSYN	265	267	ACC	901	903	AGC	175;174;174	A;G;C	147;147;150	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	V98I	NONSYN	292	294	GTC	928	930	ATC	168;169;170	A;T;C	143;142;147	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	.	MULTIPLE	358	359	AA	993	994	CG	178;178	C;G	150;151	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	.	MULTIPLE	361	362	GA	996	998	CAG	178;176;177	C;A;G,A	148;147;141,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	N122K	NONSYN	364	366	AAC	1000	1002	AAA	177;177;177	A;A;A	149;147;144	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	1027	1029	TAT	179;179;179	T;A,G;T,G,A	147;147,1;144,1,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	N134E	NONSYN	400	402	AAT	1036	1038	GAG	176;175;174	G;A;G,T	147;146;142,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	V135L	NONSYN	403	405	GTG	1039	1041	CTT	175;176;175	C;T;T	147;147;146	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	G140K	NONSYN	418	420	GGA	1054	1056	AAA	176;177;177	A;A;A	146;150;148	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	K143E	NONSYN	427	429	AAA	1063	1065	GAA	175;174;172	G;A;A	147;145;143	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	V151A	NONSYN	451	453	GTA	1087	1089	GCA	169;171;171	G;C;A	140;141;146	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	A196V	NONSYN	586	588	GCC	1222	1224	GTC	169;168;168	G;T;C,G	146;145;145,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	T213S	NONSYN	637	639	ACA	1273	1275	TCA	173;175;173	T;C;A	149;153;150	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1393	1395	CAA	201;200;199	C;A;A	169;169;165	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	.	INDELS	760	762	ACA	1397	1401	ATCAA	200;200;200;198;197	A;T;C;A;A	163;169;170;163;163	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	.	INDELS	763	764	TG	1404	1406	AGT	197;198;199	A;G;T	164;166;169	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1411	1413	GAT	202;202;202	G,T;A;T	167,2;172;171	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	T269S	NONSYN	805	807	ACC	1447	1449	AGC	203;203;204	A,T;G;C,T	170,1;170;170,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1519	1521	AGT	219;222;223	A;G;T	180;182;182	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1525	1527	GAC	220;220;220	G;A;C	178;180;179	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1528	1530	TAC	218;218;219	T;A;C	180;183;185	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	1	SNP	p	G120K	1	.	.	358	360	AAG	993	995	CGG	178;178;178	C;G;G	150;151;145	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	1	SNP	p	D121N	0	.	.	361	363	GAC	996	999	CGC	178;177;178	C;G,A;C	148;141,1;147	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	976	porB1b	1041	1041	96.37	porB1b.l15.c4.ctg.1	2089	139.4	1	SNP	p	A121D	1	.	.	361	363	GAC	996	999	CGC	178;177;178	C;G,A;C	148;141,1;147	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	3002	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	5267	170.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	454	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1362	99.5	1	SNP	p	V57M	1	.	.	169	171	ATG	665	667	ATG	169;170;170	A,C;T;G,C	139,1;144;141,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
